Publications by authors named "Jay Andersen"

Claim this Profile
P
Patient characteristics, treatment patterns, and clinical outcomes in HER2-negative early breast cancer by germline BRCA status.
Jay A Andersen, Jagadeswara Rao Earla, Nicole Fulcher, Juliet Ndukum, Nicholas Robert

Future Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2- breast cancer.
Heather L McArthur, Sara M Tolaney, Rebecca Dent, Peter Schmid, Jamil Asselah, Jay C Andersen

Ther Adv Med Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.
Melinda L Telli, Jennifer K Litton, J Thaddeus Beck, Jason M Jones, Jay Andersen

Breast Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study.
Jennifer K Litton, J Thaddeus Beck, Jason M Jones, Jay Andersen, Joanne L Blum

Oncologist· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer.
Zhen Shi, Julia Wulfkuhle, Malgorzata Nowicka, Rosa I Gallagher, Cristina Saura, Jay Andersen

Clin Cancer Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
Peter Schmid, Javier Cortes, Rebecca Dent, Lajos Pusztai, Heather McArthur, Jay Andersen

N Engl J Med· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy in Early-Stage Invasive Breast Cancer.
Joanne L Blum, Nicholas Robert, Jay Andersen, Anne Favret, Patrick Ward

J Clin Oncol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.
Denise A Yardley, James Reeves, E Claire Dees, Cynthia Osborne, Devchand Paul, Jay Andersen

Clin Breast Cancer· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis